← Leaderboards
William R Tyor
Veterans Health Administration
$6,673,682
Attributed
$14,218,808
Total exposure
8
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2M · FY2013–25$2M$1.5M$1M$500K$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$14,218,808 · 6
VA$0 · 2
By mechanism
R01$14,218,808 · 6
I01$0 · 2
Top collaborators
- Raymond F. Schinazi11 shared
- Michael Ilya Bukrinsky6 shared
- Dmitri Sviridov5 shared
- Christina Gavegnano4 shared
- Vincent Charles Marconi3 shared
- Albert Anderson1 shared
Most similar at Veterans Health Administration
Same institution · by research overlap
- Christina Gavegnano$2,074,187
- Walter Royal$7,226,551
- Vincent Charles Marconi$11,562,796
Others in their field
Top investigators on “Hiv Infections”
- Wafaa M. El-Sadr · Columbia University Health Sciences$965,259,079
- Lawrence Corey · Fred Hutchinson Cancer Center$728,701,834
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$467,263,656
- Judith S. Currier · University Of California Los Angeles$466,447,923
- Richard Marlink · Elizabeth Glaser Pediatric Aids Fdn$457,210,249
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$398,445,678
Research focus
Hiv InfectionsAntiretroviral TherapyBehavioralIn VivoBrainMouse ModelIn VitroScid MiceInfectionHiv-Associated Neurocognitive DisorderLeadNeuronsPathologyDoseRegimenAnimal ModelPreventCellsBehaviorExhibitsInflammationMacrophageNeuraxisMicroglia
Grant awards (38)
Novel pathogenic mechanism of HIV-associated CNS neurological disorders$672,761
R01 · FY2025 · NS
Phase II study to evaluate the efficacy and safety of baricitinib for reduction of HIV in the central nervous system$638,381
R01 · FY2025 · MH
Novel pathogenic mechanism of HIV-associated CNS neurological disorders$744,154
R01 · FY2024 · NS
Phase II study to evaluate the efficacy and safety of baricitinib for reduction of HIV in the central nervous system$638,381
R01 · FY2024 · MH
Validating a Humanized Mouse HIV Model for Cognitive Deficits and Novel Treatments$0
I01 · FY2024 · VA · contact PI
Novel pathogenic mechanism of HIV-associated CNS neurological disorders$762,862
R01 · FY2023 · NS
Phase II study to evaluate the efficacy and safety of baricitinib for reduction of HIV in the central nervous system$638,381
R01 · FY2023 · MH
Supplement to R01 NS124477$34,154
R01 · FY2023 · NS
Validating a Humanized Mouse HIV Model for Cognitive Deficits and Novel Treatments$0
I01 · FY2023 · VA · contact PI
Novel pathogenic mechanism of HIV-associated CNS neurological disorders$680,858
R01 · FY2022 · NS
Towards Suppression and Elimination of HIV in the CNS$673,447
R01 · FY2022 · MH
Phase II study to evaluate the efficacy and safety of baricitinib for reduction of HIV in the central nervous system$638,381
R01 · FY2022 · MH
Validating a Humanized Mouse HIV Model for Cognitive Deficits and Novel Treatments$0
I01 · FY2022 · VA · contact PI
Mechanisms of Interferon-alpha Neurotoxicity$0
I01 · FY2022 · VA · contact PI
Novel pathogenic mechanism of HIV-associated CNS neurological disorders$730,589
R01 · FY2021 · NS
Towards Suppression and Elimination of HIV in the CNS$680,675
R01 · FY2021 · MH
Mechanisms of Interferon-alpha Neurotoxicity$0
I01 · FY2021 · VA · contact PI
Towards Suppression and Elimination of HIV in the CNS$691,957
R01 · FY2020 · MH
Mechanisms of Interferon-alpha Neurotoxicity$0
I01 · FY2020 · VA · contact PI
Towards Suppression and Elimination of HIV in the CNS$688,871
R01 · FY2019 · MH
Mechanisms of Interferon-alpha Neurotoxicity$0
I01 · FY2019 · VA · contact PI
Towards Suppression and Elimination of HIV in the CNS$660,576
R01 · FY2018 · MH
Therapeutics Targeting Macrophages/Microglia to Eradicate CNS HIV-1 Reservoirs$728,247
R01 · FY2017 · MH
Interferon-Alpha-Neurotoxicity$0
I01 · FY2017 · VA · contact PI
Therapeutics Targeting Macrophages/Microglia to Eradicate CNS HIV-1 Reservoirs$833,525
R01 · FY2016 · MH
Interferon-Alpha-Neurotoxicity$0
I01 · FY2016 · VA · contact PI
Therapeutics Targeting Macrophages/Microglia to Eradicate CNS HIV-1 Reservoirs$744,210
R01 · FY2015 · MH
Therapeutics Targeting Macrophages/Microglia to Eradicate CNS HIV-1 Reservoirs$81,089
R01 · FY2015 · MH
Interferon-Alpha-Neurotoxicity$0
I01 · FY2015 · VA · contact PI
Therapeutics Targeting Macrophages/Microglia to Eradicate CNS HIV-1 Reservoirs$649,686
R01 · FY2014 · MH
Interferon-Alpha-Neurotoxicity$0
I01 · FY2014 · VA · contact PI
Therapeutics Targeting Macrophages/Microglia to Eradicate CNS HIV-1 Reservoirs$643,687
R01 · FY2013 · MH
HAART IN SCID MICE WITH HIV ENCEPHALITIS$178,750
R01 · FY2003 · MH
HAART IN SCID MICE WITH HIV ENCEPHALITIS$45,625
R01 · FY2003 · MH
HAART IN SCID MICE WITH HIV ENCEPHALITIS$178,750
R01 · FY2002 · MH
HAART IN SCID MICE WITH HIV ENCEPHALITIS$178,750
R01 · FY2001 · MH
HAART IN SCID MICE WITH HIV ENCEPHALITIS$228,750
R01 · FY2000 · MH
COCAINE EFFECTS ON HIV ENCEPHALITIS IN SCID MICE$153,311
R01 · FY2000 · DA